AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

Treatment containing Recentin demonstrated clinical benefits, but it proves worse than the current standard care treatment.

Today, a brief rundown of news from Roche and Turnstone Biologics, as well as updates from Sanofi, Pfizer and Flagship Pioneering that you may have missed. Recent biotech company acquisitions have put ...

Most patients with ovarian cancer are diagnosed at late stage as symptoms at early stages are minimal making it difficult to differentiate from common diseases. Once patients reach these late stages, ...

AstraZeneca and Merck's PARP inhibitor Lynparza has carved out blockbuster revenues across uses in breast, ovarian, prostate and pancreatic cancer, but colorectal cancer won’t be added to the list.

Drugmaker AstraZeneca said on Monday that Lynparza candidate had been approved in the US as an adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer.

Lynparza is approved in 64 countries, including those in the EU, for the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless of BRCA status.